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Background: Obesity is associated with abnormal fasting and postprandial lipids, which may link obesity with
atherosclerosis. We explored fasting and postprandial lipids in morbidly obese patients treated with sleeve
gastrectomy and in control subjects.
Methods: After fasting for 12 h 15 morbidly obese patients (BMI 51.4±6.5 kg/m2, 43.7±12.6 years) received a
standardized oral fat load before and 3 months after bariatric surgery (sleeve gastrectomy). Controls (n=9, BMI
23.1±1.4 kg/m2) were studied once. Plasma was obtained fasting and then postprandially every 2 h for 8 h.
Triglycerides (TG), chylomicron-TG (CM-TG), VLDL/chylomicron-remnant (VLDL/CR)-TG, cholesterol, LDL-cholesterol,
VLDL/CR-cholesterol and HDL-cholesterol were isolated by ultracentrifugation at each time point. Postprandial
values were expressed as area under the curve (AUC) and incremental area under the curve (iAUC). In addition,
fasting glucose and insulin values and HOMA-IR-Index was measured (n=14).
Results: Compared to controls morbidly obese patients had elevated TG and slightly altered postprandial lipids.
Following surgery (weight loss 23.4 kg±6.2 kg; p<0.001) fasting TG (−19.1%; p=0.04), VLDL/CR-TG (−20.0%; p=0.05)
decreased significantly, while fasting cholesterol, VLDL-, HDL- and LDL-cholesterol did not change. AUC and
iAUC decreased significantly for VLDL/CR-TG (−20.4%, p=0.04 and −38.5%, p=0.04, respectively). Neither fasting
nor postprandial changes correlated with the change in weight. In patients with preoperatively elevated TG
(>150 mg/dl) a similar pattern was observed. Fasting insulin and HOMA were reduced significantly (−51.9%;
p=0.004 and −47.9%; p=0.011).
Conclusions: Three months after sleeve gastrectomy fasting and postprandial lipoprotein metabolism and glucose
metabolism is improved in morbidly obese patients. The potential mechanisms may relate to decreased caloric
intake but also to hormonal changes.
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Obesity has reached epidemic proportions with 1.5 billion
overweight adults in 2008, of which 500 million were obese.
The World Health Organization (WHO) predicts that by
2015 this number will grow to 2.3 billion overweight and
700 million obese adults [1]. Obesity is defined as a body
mass index (BMI) (weight in kg divided by height in meters
squared) of greater than 30 kg/m2: It is associated with an* Correspondence: elisa.waldmann@med.uni-muenchen.de
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distribution, and reproduction in any mediumincreased risk for hypertension, dyslipidemia, type 2
diabetes, coronary heart disease, stroke, gallbladder
disease, osteoarthritis, dementia, sleep apnoea and
respiratory problems, and various cancers [2,3].
Overall mortality is increased in obese subjects [4], with
coronary heart disease being the major factor for higher
mortality [5,6]. Lipid changes such as elevated TGs, elevated
LDL-cholesterol (LDL-c) and low HDL-cholesterol
(HDL-c) are typically found in obese patients and
predispose to atherosclerosis.
The National Cholesterol Education Program (NCEP)
recommends that blood lipid profiles are examined aftertral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Mean values for fasting total (a) and VLDL (b) TGs and
iAUC of total and VLDL TGs before and 3 months after sleeve
gastrectomy (Mean + Maximum value/-Minimum value).
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independent risk factors for cardiovascular disease.
However, from a lipidological point of view most
subjects including obese persons are in a postprandial
state for most of the day. Especially TG levels and thus
the concentration of TG rich lipoproteins can increase
enormously postprandially to very high levels and it may
take more than 12 hours to reach fasting levels again [8].
It is therefore not surprising that in addition to fasting
TGs the concentration of postprandial TGs has also
been associated with cardiovascular events [9,10] and an
independent atherogenic potential has been observed
[11-14]. Newer data also highlight the importance of non-
fasting remnant cholesterol [15] as a predictor of cardio-
vascular events. Taken together these data indicate that
postprandial lipoprotein metabolism plays an important
role in atherogenesis.
As first-line therapy for obesity guidelines recommend
lifestyle modification including physical activity as well
as dietary and behavioral changes. Pharmacotherapy is
considered second - line therapy if the patient does not
respond to primary treatment. Finally, surgical therapy
(bariatric surgery) is a treatment option in patients
with a history of long-standing obesity with a BMI of
40 kg/m2 or a BMI greater than 35 kg/m2 and co morbid-
ities such as diabetes. Of all treatment options surgery in-
duces the most dramatic long-term weight loss [16]. A
number of different surgical techniques are available
for bariatric surgery (gastric banding, sleeve gastrectomy,
bypass surgeries). These techniques differ considerably
with respect to induced weight change, metabolic effects,
and complication rates [17].
Numerous studies have evaluated the effect of bariatric
surgery on fasting lipids, overall showing beneficial changes
such as lowering cholesterol, TGs and LDL-cholesterol and
increasing HDL-cholesterol [18-20]. The effect of weight
loss on postprandial lipids has been rarely evaluated.
However, this may be particularly interesting because
bariatric surgery, especially sleeve gastrectomy, not only
reduces weight but also alters gastric motility and
leads to earlier satiety, partly by earlier stimulation of
the vagal nerve due to a reduction of gastric volume.
Furthermore, during sleeve gastrectomy the ghrelin
producing area is partly removed and it is believed that
this may directly affect metabolic parameters (resulting in
the term “metabolic surgery”).
Thus, the aim of our study was to evaluate the effect
of bariatric surgery on fasting and postprandial lipid
levels in morbidly obese patients and to compare the
effect to normolipidemic control subjects.
Results
All subjects had significant weight loss 3 months after
surgery (mean weight loss 23.4 kg±6.2 kg; p<0.001).Fasting plasma (−19.1%; p=0.04) and VLDL/CR-TGs
(−20.0%; p=0.05) decreased significantly (Figure 1) even
beyond the level of the control group while plasma
cholesterol and LDL-cholesterol were reduced and
HDL-cholesterol was increased but did not change
significantly (Table 1). Furthermore, there was a trend
towards a decrease in the concentration of LDL/
HDL-TGs (infranatant of ultracentrifugation).
Following the oral fat load, the area under the curve
(AUC) for TGs decreased significantly for VLDL/CR-TG
(−26.2%, p=0.017) (Table 1, Figure 2). The incremental area
under the curve (iAUC) also changed significantly for
VLDL/CR-TG (−17.6%; p=0.04) and improved for the other
parameters, but these changes were not significant (Table 1).
Furthermore, compared to controls, obese patients had a
later peak of TG concentrations (plasma, CM and CR).
Bariatric surgery induced a shift towards a later time point
in the CR fraction while peak was shifted to an earlier time
point in the CM fraction (Table 2, Figure 2). However none
of these changes were significant.
Neither the changes in fasting values nor the postprandial
changes correlated with the change in weight. We also did
not observe any other meaningful correlations.
Table 1 Fasting lipid parameters (mg/dl), AUC and incremental AUC (mg x h/dl) in patients before and after bariatric
surgery and in control subjects (Data are expressed in mean ± SD); the indicated p-value relates to the comparison
before-after surgery (as measured by Wilcoxon-test)
Controls Before surgery After surgery Change [%] p
Fasting
Plasma-triglycerides 117 ±29 141 ±42 114 ±26 −19.1 0.036
Plasma-cholesterol 188 ±42 175 ±28 169 ±31 −3.4 0.256
HDL-cholesterol 56 ±14 42 ±10 44 ±9 +4.8 0.294
LDL-cholesterol 108 ±35 105 ±25 103 ±29 −1.9 0.691
VLDL/CR-triglycerides 92 ±28 115 ±47 92 ±27 −20.0 0.053
VLDL/CR-cholesterol 19 ±11 20 ±8 17 ±5 −15.0 0.099
LDL/HDL-triglycerides 39 ±11 39 ±8 36 ±7 −7.7 0.197
AUC
Plasma-triglycerides 123 ±412 1468 ±490 1222 ±309 −16.8 0.078
CM-triglycerides 377 ±299 368 ±214 288 ±121 −21.7 0.670
VLDL/CR-triglycerides 789 ±307 1078 ±449 858 ±295 −20.4 0.036
iAUC
Plasma-triglycerides 396 ±268 410 ±238 338 ±159 −17.6 0.394
CM-triglycerides 327 ±254 306 ±194 241 ±129 −21.2 0.280
VLDL/CR-triglycerides 202 ±126 288 ±187 177 ±140 −38.5 0.044
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elevated TGs (>150 mg/dl; n=5) indicated that patients with
normal TG levels before surgery had neither significant
changes in fasting data nor in AUC and iAUC data.
In patients who had elevated fasting TG before the
study a significant decrease of fasting plasma- and
VLDL/CR-TG (−38%, p= 0.04; -45%, p=0.04) was observed.
However, no significant changes in any of the postprandial
parameters were seen (Table 3).
Analysis of parameters of glucose metabolism showed
a significant reduction of fasting insulin (−51.9%,
p=0.004), while glucose values did not change significantly.
All but one patient (HOMA-IR = 2.22) had HOMA-IR
>2.5. Insulin resistance improved significantly after surgery
(−47.9%, p=0.01; Table 4). A subgroup analysis of patients
with HOMA-IR >5 (n=9) compared to HOMA-IR <5
(n=5) showed a difference in absolute values of AUC and
iAUC. However, due to the considerable inter-individual
variation this difference was not statistically significant.
Discussion
In this study we evaluated lipoprotein metabolism following
bariatric surgery. Since it is well known that fasting
levels of lipids improve considerably after bariatric
surgery [18,19,21] we hypothesized that postprandial
lipid metabolism would also significantly improve as
shown by a reduction in the iAUC of TGs.
Three months after surgery fasting TGs as well as
VLDL/CR-TGs decreased significantly by approximately
20% (Table 1). The decrease in lipid parameters issomewhat less than reported in previous studies
[22,23]. In contrast to other studies we also did not
see a significant change in HDL-cholesterol. The observed
difference between ours and previous studies may relate
to the fact that in previous studies reevaluation was
performed 6 months or even 12 months after surgery,
while our patients were studied three months after surgery
and therefore had lost less weight. Although it would be
most interesting to evaluate lipid metabolism before
surgery, then at the time point of the most rapid weight
loss and again at a new steady state, this is difficult to
perform since the time course of weight loss is highly
variable. In comparing our study to previous studies it
should also be acknowledged that our subjects received a
sleeve gastrectomy, a form of bariatric surgery for which
only minimal data on lipid metabolism is available
[20,24,25]. Thus, it could be hypothesized that the method
of surgery has an impact on lipid levels. None of the other
fasting lipid parameters changed significantly compared to
baseline, although we observed a trend towards a higher
HDL-cholesterol and lower total cholesterol.
In addition to the significant changes in fasting TGs,
we also observed changes in postprandial lipoprotein
metabolism. The observed alterations in AUC of VLDL/
CR-TG primarily reflect the reduction of fasting concen-
trations. The primary endpoint, the more specific iAUC,
also changed significantly for VLDL/CR-TG. This is in
line with data on dietary induced weight reduction
showing an improvement in fasting and postprandial
lipids [26]. Similarly, it was shown that drugs for weight
Figure 2 Means (± SD) of plasma - (a), CM- (b) and VLDL/CR- (c)
TGs following the oral fat load. Filled and unfilled symbols
represent data obtained before and after bariatric surgery. Crosses
symbol control group.
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postprandial TGs [27,28]. Although our results compare
favorably to previously published data, some peculiarities
of our study should be kept in mind: First, in our patients,
the postoperative evaluation was performed while the
subjects were still losing weight, thus before reaching a
new steady-state, while studies evaluating diets or drugs
were performed in steady-state. The already significant
reduction in iAUC of VLDL/CR-TG 3 months after
surgery indicates that further weight loss may result
in a further improvement of postprandial lipoprotein
metabolism. Second, since patients were not selectedfor abnormal lipids, they were characterized pre-operatively
by a relatively normal fasting and postprandial lipoprotein
metabolism, although obesity is associated with hypertri-
glyceridemia. There is no clear relationship between BMI
and TGs. In fact, in our own experience less than half of
patients presenting for bariatric surgery (n=52) have
hypertriglyceridemia [20]. However, when we looked at the
subgroup of patients with preoperatively elevated fasting
TGs (>150 mg/dl) we did not observe a stronger effect of
surgery on fasting or postprandial lipoprotein metabolism
probably due to the small size of the group.
It is currently unclear which mechanisms are responsible
for these changes. Most likely an improved handling of
TG-rich lipoproteins (and not an altered production)
is responsible for the improved postprandial lipoprotein
metabolism. In particular, LPL activity and CETP mediated
processes may change as a consequence of dramatic weight
change or as a consequence of an improved glucose
metabolism. Future studies need to address the underlying
mechanisms.
Independent of the underlying mechanisms, the decrease
in postprandial TG concentrations reflects a decreased
number of remnant particles, which in the light of recent
findings probably translates into a significantly decreased
cardio-vascular risk.
Bariatric surgery induced a significant decrease in
fasting insulin levels while fasting glucose did not change,
resulting in a significant improvement of HOMA-IR
index. This data is in line with previously published data
[20,29], although it is especially interesting since previous
studies showed same results after a longer period of follow
up. Thus the positive effect on insulin sensitivity seems to
be evident rather early after bariatric surgery. The reason
for these changes may relate to the caloric restriction, the
induced weight change or hormonal changes directly
induced by bariatric surgery. Nevertheless these data are
in good agreement with previous studies [30] showing that
diabetes or insulin resistance may lead to an altered
postprandial lipid response which in turn may contribute
to the higher cardiovascular risk in diabetic patients.
A somewhat surprising finding of the study was that
bariatric surgery had a heterogeneous effect on the peak
time of TG concentrations in different lipoprotein
fractions. While the peak shifted to an earlier time point
in the CM fraction it shifted to a later time point in the
VLDL/CR fraction. It should be noted that in the control
subjects TG concentrations peaked earlier in all fractions.
Since surgery induced a normalization of many metabolic
parameters, one could have had speculated that peak time
would decrease following bariatric surgery in all fractions.
The reason for the observed delay in the VLDL/CR
fraction is not known. A number of studies have indicated
that bariatric surgery, especially sleeve gastrectomy,
induces changes in the secretion and concentration of
Table 2 Time point (in hours) of peak TG concentration
(mean ± SD) following an oral fat load; the indicated
p-value relates to the comparison before-after surgery








Plasma-triglycerides 2.89±1.45 3.87±1.41 4.53±1.77 17.24 0.42
CM-triglycerides 3.78±1.56 5.07±1.83 4.40±2.03 −13.16 0.36
VLDL/CR-triglycerides 3.11±1.76 3.87±1.60 4.27±2.25 10.34 0.52
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motility [29].
Several limitations of our study should be noted. First
the number of subjects evaluated in this trial is small,
which raises the possibility of a type II error. Furthermore,
the patient group was heterogeneous with respect to
underlying lipid parameters. When we started our study
it was unclear whether and to what extent patients
undergoing bariatric surgery would benefit regarding
their postprandial lipid metabolism. Subsequent studies
should focus on more homogenous patient groups for
example patients with well defined lipid disorders and
should include a longer follow up period. Another limita-
tion relates to the method used to evaluate postprandial
lipid metabolism. We primarily relied on triglyceride
concentrations. It is unclear whether the measurement of
apoB-48 concentrations and/or the use of retinyl-palmitate
as used in previous studies provide significant additional
information [27,31]. Currently there is no widely accepted
approach incorporating information from triglyceride,Table 3 Fasting lipid parameters and AUC (mg x h/dl;
means ± SD) in patients with preoperatively high TGs
(>150 mg/dl; n=5); the indicated p-value relates to the








Plasma-triglycerides 184 ±36 114 ±26 −38 0.043
CM-triglycerides 10 ±5 9 ±13 −10 ns
VLDL/CR-triglycerides 166 ±37 92 ±27 −45 0.043
AUC
Plasma-triglycerides 1779 ±597 1222 ±309 −31 ns
CM-triglycerides 420 ±229 288 ±121 −31 ns
VLDL/CR-triglycerides 1400 ±549 858 ±295 −39 ns
iAUC
Plasma triglycerides 432 ±268 338 ±159 −22 ns
CM-triglycerides 337 ±205 241 ±129 −29 ns
VLDL/CR-triglycerides 253 ±253 177 ±140 −30 ns
ns = not significant.apoB-48 and retinyl palmitate into one model. However,
future studies should incorporate further measurement of
these parameters and in addition address aspects of
potential underlying mechanisms.
Conclusion
Three months after bariatric surgery fasting, postprandial
lipoprotein metabolism and insulin sensitivity improved
significantly in morbidly obese subjects. In the long-term
this may lead to a reduction of cardiovascular events.
Methods
Postprandial studies were performed in 15 morbidly
obese subjects (6 male, 9 female, BMI 51.4±6.5 kg/m2,
43.7±12.6 years) and 9 normolipidemic controls (5 male,
4 female, age 34.0±10.5 years, BMI 23.1±1.4 kg/m2).
Normolipidemic subjects were studied once and obese
subjects were studied twice, once before bariatric surgery
and once 3 months after surgery. All 15 obese subjects had
bariatric surgery (sleeve gastrectomy) at the Department of
Surgery – Grosshadern. Two of the study subjects were on
simvastatin (10 mg/d) throughout the study period.
The study was approved by the Ethics Committee of the
Medical Faculty of the Ludwig-Maximilians-University
Munich and all subjects gave written, informed consent
for participation in the study.
Postprandial study
The postprandial studies were performed as described pre-
viously [27] with slight modifications. Each postprandial
study was performed after subjects had fasted for 12 h.
After obtaining fasting blood, subjects received a fatty meal
consisting of 50 g oil, 120 g cream, 20 g fluid egg, 10 g
sugar, 1.8 g coffee flavor in a cream shake of 200 ml.
Compared to previous studies the volume of the test meal
had to be reduced to account for the reduced gastric
volume of about 100 ml after bariatric surgery [32].
This fat load yields 858 kcal and contains 88 g fat,
188 mg cholesterol, 14 g carbohydrates, 5, 6 g proteins. It
was ingested within 5 min. Following the fat load, blood
samples were taken every 2 h for 8 h. During that time,
subjects did not eat or drink calories but were allowed toTable 4 Glucose (mg/dl), insulin-values (μU/ml) and
HOMA-index in patients (n=14) before and after bariatric
surgery (Data are expressed in mean ± SD); the indicated
p-value relates to the comparison before-after surgery
(as measured by Wilcoxon-test)
Before surgery After surgery Change [%] p
Fasting
Glucose 100.1 ±25.2 98.9 ±23.9 −1.3 0.551
Insulin 28.9 ±18.1 13.9 ±5.9 −51.9 0.004
HOMA 6.8 ±3.4 3.5 ±2.1 −47.9 0.011
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procedure was performed before and 3 months after
bariatric surgery and once in normolipidemic controls.
Analytical methods
Blood samples were drawn in tubes containing EDTA-
sodium. Plasma was isolated by centrifugation (10 min,
3000 rpm). Ultracentrifugation of each plasma sample was
performed to obtain two fractions of TG-rich lipoproteins:
CM and VLDL/CR. To separate CM from VLDL/CR, 3 ml
of plasma in a Beckman-tube were overlaid with a solution
of d=1.006 kg/l and centrifuged for 20 min at 20,000 rpm
(Ti 50.4 rotor; Beckman Coulter, Inc., Palo Alto, CA). The
supernatant, containing the CMs, was removed using a
Beckman tube slicer, whereas the infranatant was used to
obtain VLDL/CR by further ultracentrifugation (d=1.006
kg/l, Ti 50.4 rotor, 18 h, 40,000 rpm). In plasma and in both
lipoprotein fractions, cholesterol and TG concentrations
were determined. In plasma the concentrations of HDL-
cholesterol and LDL-cholesterol were also determined. TG
and cholesterol concentrations were measured by using the
Alcyon lipid analyzer (Alcyon 300; Abbott Laboratories, IL)
and the appropriate commercial kit (Roche Molecular
Biochemicals). Postprandial metabolism was quantified
by calculating the area under the curve (AUC) and
the incremental AUC for plasma-, CM- and VLDL-TGs
and -cholesterol, plasma HDL, LDL, TGs and cholesterol in
the infranantant. Concentrations obtained over the 8 h
period following the ingestion of the fat meal were used for
this calculation. Areas under the curve (AUC) for TGs were
calculated using the linear trapezoidal method as previously
described [27]. The incremental AUC was determined as
the AUC minus the baseline or fasting concentration.
Fasting insulin and glucose were determined in plasma
samples by the Department of Clinical Chemistry at the
University of Munich (LMU) using photometry and
elektrochemiluminescence (Beckmann Coulter AU680 and
Roche Cobas E 411). Insulin sensitivity was evaluated using
the Homeostasis Model Assessment of Insulin Resistance
(HOMA-IR) as previously described [33].
Statistical analysis
A paired comparison was performed to analyze our data.
The primary endpoint was the incremental area under
the TG curve following the standardized oral fat
challenge. The sample size estimation (n=16) is based on
a two-sided significance of 0.05, a statistical power of
80%, an estimated change of 10% and a variance of 15%.
Initially 20 patients undergoing bariatric surgery, including
sleeve gastrectomy (n=15), gastric banding (n=3) and
gastric bypass (n=1) were recruited for the study. Due to
the great heterogeneity related to the different surgical
methods only patients undergoing sleeve gastrectomy were
chosen for this analysis. Differences between parametersobtained before and after bariatric surgery were evaluated
by calculating arithmetic means ±SD. Range is given
in parenthesis. To test for statistical significance we
used non parametrical Wilcoxon test analysis. To
measure linear relationship we used Pearsons Correlation
coefficient. These tests were performed using the SPSS,
Inc. software (SPSS, Inc., Chicago, IL). The critical P value
for significance was set at 0.05.
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